These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19183107)

  • 21. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
    Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G
    Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations.
    Meidan VM; Glezer J; Salomon S; Sidi Y; Barenholz Y; Cohen JS; Lilling G
    J Liposome Res; 2006; 16(1):27-43. PubMed ID: 16556548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
    Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L
    Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural and functional studies on the stalk of the transferrin receptor.
    Dukovski D; Li Z; Kelly DF; Mack E; Walz T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):712-6. PubMed ID: 19258014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE; Albritton KH; Bastar JD; Randall RL
    J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
    Yu B; Mao Y; Bai LY; Herman SE; Wang X; Ramanunni A; Jin Y; Mo X; Cheney C; Chan KK; Jarjoura D; Marcucci G; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Blood; 2013 Jan; 121(1):136-47. PubMed ID: 23165478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
    Kim R; Tanabe K; Uchida Y; Emi M; Toge T
    Int J Mol Med; 2003 Jun; 11(6):799-804. PubMed ID: 12736725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma.
    Benimetskaya L; Wittenberger T; Stein CA; Hofmann HP; Weller C; Lai JC; Miller P; Gekeler V
    Clin Cancer Res; 2004 Jun; 10(11):3678-88. PubMed ID: 15173074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of sequence-defined oligoaminoamides with transferrin-polycation conjugates for receptor-targeted gene delivery.
    Zhang W; Rödl W; He D; Döblinger M; Lächelt U; Wagner E
    J Gene Med; 2015; 17(8-9):161-72. PubMed ID: 26227403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cationic lipids enhanced cellular uptake and activity of bcl-2 antisense oligodeoxynucleotide G3139 in HL-60 cells.
    Zhu YG; Zhuo GS; Chen ZZ; Chen XC
    Acta Pharmacol Sin; 2001 Nov; 22(11):1007-12. PubMed ID: 11749792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells.
    Benimetskaya L; Guzzo-Pernell N; Liu ST; Lai JC; Miller P; Stein CA
    Bioconjug Chem; 2002; 13(2):177-87. PubMed ID: 11906253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
    Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of Antisense Oligonucleotide LOR-2501 Using Transferrin-conjugated Polyethylenimine-based Lipid Nanoparticle.
    Zheng B; Yang S; Tian Q; Xie Y; Zhang S; Lee RJ
    Anticancer Res; 2019 Apr; 39(4):1785-1793. PubMed ID: 30952718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Why G3139 works poorly in cancer trials but might work well against HIV.
    Parris GE
    Med Hypotheses; 2007; 69(3):537-40. PubMed ID: 17363184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.